Korro Bio raised $91.5 million to run its platform of single-base RNA edits to treat a range of diseases.
The Cambridge based biotech will use the cash haul toward getting its preclinical program into the clinic, while also “establishing a broad portfolio of innovative RNA editing therapies.”
The financing was led by Wu Capital with help from current investors Atlas Venture and New Enterprise Associates. Additional new investors include Qiming Venture Partners USA, Surveyor Capital (a Citadel company), Cormorant Asset Management, MP Healthcare Venture Management and Alexandria Venture Investments.
KORRO bio is creating transformative therapeutics for patients by selectively editing messenger RNA to recode specific codons to deliver a beneficial change in protein sequence, structure and function.